Advancing CML Management Towards an Ideal Patient Journey
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
- What excites you most about the potential advancements in CML management that may be on the horizon in the next 5-10 years?
- How do you envision the CML patient experience being transformed compared to today?
Recent Videos
Related Content
Pirtobrutinib May Provide Benefit in Treatment Sequencing of Relapsed/Refractory CLL/SLL
December 12th 2024Article
Treatment with pirtobrutinib induced superior progression-free survival among heavily pretreated patients with relapsed or refractory CLL/SS previously treated with a covalent BTK inhibitor.
